Business
Banks hold FTSE 100 back on windfall tax worry
The FTSE 100 ended Friday on the back foot as banking stocks came under pressure amid reports that the UK Government is considering a windfall tax on the sector.
The FTSE 100 index closed down 29.48 points, 0.3%, at 9,187.34.
The FTSE 250 ended 138.68 points lower, 0.6%, at 21,605.72 but the AIM All-Share finished up 2.89 points, 0.4%, at 764.10.
For the week, the FTSE 100 shed 1.3%, the FTSE 250 fell 1.0% and the AIM All-Share rose 0.4%.
Banking stocks in London were rocked by reports that Chancellor Rachel Reeves could target the sector to help shore up public finances.
Lenders NatWest, Lloyds Banking Group and Barclays PLC fell 4.9%, 3.4% and 2.2% respectively in London.
On Friday, a report by the Institute for Public Policy Research said the Treasury should impose a new levy to recoup “windfalls” made by lenders as a legacy of the Bank of England’s quantitative easing programme, undertaken in the wake of the financial crisis.
The think-tank said the UK taxpayer is spending £22 billion a year compensating the BoE for losses on the programme.
The scheme entailed the BoE purchasing hundreds of billions of pounds of government bonds, buoying commercial bank reserves at the central bank.
These are now being remunerated at the BoE’s official rate, which stands at 4.0%.
The IPPR recommended that the Treasury introduce a QE reserves income levy on commercial banks to save £7 billion to £8 billion a year over this parliament.
In addition, it suggests the BoE slows down quantitative tightening, by ending its fire sale of government bonds, to save more than £12 billion a year.
The Financial Times on Friday said fears are mounting that the autumn budget will target banks to help fill a £20 billion fiscal hole.
“Politically it is an easy target,” a senior banker told the FT. “No-one likes banks, they are seen as a whipping boy for the Government.”
Kathleen Brooks, research director at XTB, said August has seen a “torrent of leaks” from government and the Treasury about potential tax rises, ahead of the autumn budget.
“Tax rises that have been proposed include increases in capital gains tax, property tax rises, national insurance hikes on rental income and a levy on banks, among others.
“The impact of this drip feed of potential tax rises is eroding confidence and dimming the prospects for the UK economy. It is also starting to impact UK asset prices,” she said.
Faring better, ConvaTec, which rose 1.4% as interim chief executive Jonny Mason and interim chief financial officer Fiona Ryder picked up £167,000 of shares between them.
They took their interim roles after chief executive Karim Bitar went on a medical leave of absence earlier this month.
Prudential rose 2.3% as Bank of America said the insurer was its top sector pick, highlighting forecast dividend growth and share buybacks.
In New York at the time of the London equities close, the Dow Jones Industrial Average was down 0.4%, the S&P 500 was 0.7% lower, while the Nasdaq Composite was down 1.0%.
Across the pond, traders weighed a pick-up in inflation, albeit in line with expectations.
The Bureau of Economic Analysis said the headline personal consumption expenditures price index rose 0.2% month-on-month in July, slowing from 0.3% growth in June, and by 2.6% year-on-year, the rate unchanged from June.
Excluding food and energy, core PCE price index increased 0.3% on-month, the same pace of growth as in June, and by 2.9% on-year, accelerating from 2.8% in the 12 months to June.
The figures were in line with FXStreet-cited market consensus.
Core PCE is the Federal Reserve’s preferred inflationary gauge, and Friday’s reading will play an important part in how the FOMC acts at its September meeting.
The yield on the US 10-year Treasury was at 4.22%, flat from Thursday. The yield on the US 30-year Treasury was 4.93%, stretched from 4.89%.
The pound eased to 1.3510 US dollars late on Friday in London, compared to 1.3513 US dollars at the equities close on Thursday.
The euro rose to 1.1699 US dollars, against 1.1668 US dollars. Against the yen, the dollar was trading lower at 146.92 yen, compared to 147.02 yen.
In Europe, the CAC 40 in Paris ended down 0.7%, while the DAX 40 in Frankfurt closed 0.6% lower.
In London, takeover activity kept traders busy.
John Wood finally agreed a bid of about £210 million from long-term suitor Dar Al-Handasah Consultants Shair and Partners Holdings, known as Sidara, worth 30 pence for each Wood share.
In addition, Sidara said it will provide a 450 million US dollar capital injection into John Wood to provide financial stability, although the long-running takeover saga remains subject to several conditions.
John Wood chief executive Ken Gilmartin said the deal brings “us closer to finalising a challenging chapter in Wood’s history”.
“The acquisition by Sidara will solve our near-term liquidity challenges and strengthen the company in the longer term,” he added.
The agreement is subject to a number of conditions including publication of 2024 audited accounts on or before the end of October and the audit opinion not being the subject of any modified opinion in relation to the 2024 balance sheet.
Shares in Wood are currently suspended at 18.20p pending publication of 2024 accounts.
Meanwhile, JTC shot up 18% for a market value of £1.92 billion as it said its board has rejected a takeover proposal from private equity firm Permira Advisers.
Earlier on Friday, Permira said it approached the Jersey-based professional services company regarding a possible cash offer for the business.
Permira and JTC did not detail the terms of any potential offer.
However, Bloomberg reported, citing people with knowledge of the matter, that Permira has made a proposal to purchase JTC that values it at about £2 billion.
“We think there is quite a good chance of a bid – this is a market that PE has been active in and that Permira knows well,” analysts at RBC Capital Markets said.
A barrel of Brent traded at 67.41 US dollars late Friday, down from 67.51 US dollars on Thursday. Gold climbed to 3,445.38 US dollars an ounce against 3,407.04 US dollars on Thursday.
The biggest risers on the FTSE 100 were Rentokil Initial, up 9.0p at 365.0p, Prudential, up 22.2 pence at 988.6p, Fresnillo, up 35.0p at 1,788.0p, Endeavour Mining, up 44.0p at 2,536.0p, and ConvaTec, up 3.2p at 236.5p.
The biggest fallers on the FTSE 100 were NatWest, down 26.0p at 510.6p, JD Sports Fashion, down 4.0p at 96.0p, Lloyds Banking Group, down 2.7p at 79.5p, Barclays, down 8.2p at 360.4p and Kingfisher, down 5.9p at 257.4p.
Monday’s local corporate calendar has a trading statement from Workday partner and provider of IT services, Kainos Group, and half-year results from leisure and entertainment company, XP Factory.
The global economic calendar on Monday has a slew of manufacturing PMI releases, eurozone unemployment figures, and UK mortgage approvals data. US financial markets are closed for Labour Day.
Contributed by Alliance News
Business
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025.
Mike Blake | Reuters
Eli Lilly on Monday said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect, building on efforts by the company and the Trump administration to make the medicine more accessible.
The announcement also comes weeks after chief rival Novo Nordisk unveiled additional discounts on the cash prices of its obesity and diabetes drugs.
Starting Monday, cash-paying patients with a valid prescription can get the starting dose of Zepbound vials for as low as $299 per month on LillyDirect, down from a previous price of $349 per month. They can also access the next dose, 5 milligrams, for $399 per month and all other doses for $449 per month, down from $499 per month across those sizes.
Zepbound carries a list price of roughly $1,086 per month. That price point, and spotty insurance coverage for weight loss drugs in the U.S., have been significant barriers to access for some patients.
Eli Lilly’s announcement comes just weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to get and afford. The agreements will cut the prices the government pays for the drugs, introduce Medicare coverage of obesity drugs for the first time for certain patients and offer discounted medicines on the government’s new direct-to-consumer website launching in January, TrumpRx.
But Eli Lilly’s deal with Trump centers around lowering the prices of a different form of Zepbound – a multi-dose pen – after it wins Food and Drug Administration approval.
That means Eli Lilly’s Monday announcement around cutting prices on the existing single-dose vials could allow more patients to get discounted treatments more quickly.
“We will keep working to provide more options — expanding choices for delivery devices and creating new pathways for access — so more people can get the medicines they need,” said Ilya Yuffa, president of Lilly USA and global customer capabilities, in a statement.
Eli Lilly’s stock, which has climbed more than 36% this year, fell nearly 2% on Monday. Its meteoric rise due to the success of Zepbound and its diabetes injection Mounjaro vaulted it to becoming the first health-care company to hit a $1 trillion market value last month. Though cutting prices means lower revenue per medication sold, Eli Lilly’s sales — and shares — have continued to soar through past pricing announcements as demand balloons.
With single-dose vials, patients need to use a syringe and needle to draw up the medicine and inject it into themselves. Eli Lilly first introduced that form of Zepbound in August 2024.
It’s unclear how many patients are currently using single-dose vials of Zepbound. But Eli Lilly previously said that direct-to-consumer sales now account for more than a third of new prescriptions of Zepbound.
Novo Nordisk earlier this month lowered the price of its obesity drug Wegovy and diabetes treatment Ozempic for existing cash-paying patients to $349 per month from $499 per month. That excludes the highest dose of Ozempic.
The company also launched a temporary introductory offer, which will allow new cash-paying patients to access the two lowest doses of Wegovy and Ozempic for $199 per month for the first two months of treatment.
Business
OGRA Announces LPG Price Increase for December – SUCH TV
The Oil and Gas Regulatory Authority (OGRA) has approved a fresh increase in the price of liquefied petroleum gas (LPG), raising the cost for both domestic consumers and commercial users.
According to the notification issued, the LPG price has been increased by Rs7.39 per kilogram, setting the new rate at Rs209 per kg for December. As a result, the price of a domestic LPG cylinder has risen by Rs87.21, bringing the new price to Rs2,466.10.
In November, the price of LPG stood at Rs201 per kg, while the domestic cylinder was priced at Rs2,378.89.
The latest price hike is expected to put additional pressure on households already grappling with rising living costs nationwide.
Business
Taxable Value Of Goods Surges 15% In Sep-Oct As GST Cuts Boost Consumption
New Delhi: The taxable value of all supplies under GST surged by a robust 15 per cent during September-October this year, compared to the same period in 2024 due to sharp increase in consumption triggered by the tax rate cuts on goods across sectors that kicked in from September 22, according to official sources.
The growth in the same two-month period last year was 8.6 per cent. “This surge in taxable value during ‘Bachat Utsav’ demonstrates strong consumption uplift, stimulated by reduced rates and improved compliance behaviour,” a senior official said.
He pointed out that the growth has especially been strong in sectors where rate rationalisation was implemented, such as FMCG, pharma goods, food products, automobiles, medical devices and textiles. In these sectors, the taxable value of supplies has seen significantly higher growth, confirming that lower GST rates translated directly into higher consumer spending.
“It vindicates our strategy that reducing rates on essentials and mass-use sectors would create demand-side buoyancy — a Laffer Curve–type demand uplift,” he explained.These trends confirm that GST next-gen reforms have not disrupted revenue stability, and that consumption-side buoyancy has begun to translate into higher taxable value in key sectors.
This growth is in value terms which means that since GST rates were lower, the growth in volume terms will be even higher. It is clearly visible that while the Next Gen Reforms resulted in significant Bachat — increased consumption, industry has been very proactive in passing on the GST savings to the final consumers and ensuring that there is no supply side deficiency.
As GDP private consumption data will be released much later, GST taxable value serves as the most reliable real-time proxy for consumption, and the current numbers clearly indicate sustained demand expansion, the official added.
-
Sports1 week agoWATCH: Ronaldo scores spectacular bicycle kick
-
Entertainment1 week agoWelcome to Derry’ episode 5 delivers shocking twist
-
Politics1 week agoWashington and Kyiv Stress Any Peace Deal Must Fully Respect Ukraine’s Sovereignty
-
Business1 week agoKey economic data and trends that will shape Rachel Reeves’ Budget
-
Politics1 week ago53,000 Sikhs vote in Ottawa Khalistan Referendum amid Carney-Modi trade talks scrutiny
-
Tech6 days agoWake Up—the Best Black Friday Mattress Sales Are Here
-
Fashion1 week agoCanada’s Lululemon unveils team Canada kit for Milano Cortina 2026
-
Tech1 day agoGet Your Steps In From Your Home Office With This Walking Pad—On Sale This Week
